StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
8143.HK$0.08+0.00%
Fair $0.08+0.0%

8143.HK

Good Fellow Healthcare Holdings Limited

Healthcare / Medical Care FacilitiesHKSE

$0.08

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.08Fund rank 28/100 · Data gapFallback financials|
SA 26/D
F-Score: 6/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $-3.8M · quality 51.7/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 15/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

26/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists. Revenue has declined for 2 consecutive years ROE is 1.6%, below the 5% threshold
Thesis & Journal · 8143.HKLocal privado en este navegador · Good Fellow Healthcare Holdings Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$90M

P/E

N/A

•

EV/EBITDA

34.9x

↑

ROE

155.6%

↑

Gross Margin

51.9%

↑

Debt/Equity

-1.62

↓
52-Week Range$0
$0$0

TradingView lightweight chart

8143.HK price, volumen y niveles de valoración

Último $0.080Periodo -100.0%
Fair value: $0.080

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-33.3%

FCF CAGR

—

FCF margin

16.0%

FCF / Net income

-0.25x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $16.1M · net income $-10.1M · FCF $2.6M

2022-FY → 2025-FY

Gross margin

51.9%+2.8% pts

Operating margin

-67.5%-5.8% pts

Net margin

-62.8%-39.4% pts

FCF margin

16.0%+61.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$16.1M$16.1M$39.0M$55.4M$54.2M
Net Income$-10.1M$-10.1M$-17.1M$-5.9M$-12.7M
EBITDA$1.9M$1.9M$-10.1M$1.8M$4.4M
EPS-0.01-0.01-0.02-0.01-0.02
Gross Margin51.9%51.9%47.9%48.8%49.2%
Operating Margin-67.5%-67.5%-26.0%-17.7%-61.7%
Net Margin-62.8%-62.8%-43.9%-10.6%-23.4%
Balance Sheet
Debt/Equity-1.62-1.622.810.200.25
Current Ratio10.2710.27———
Cash Flow
Free Cash Flow$2.6M$2.6M$-15.3M$-3.8M$-24.5M
Returns
ROE155.6%155.6%-392.7%-26.5%-42.9%
Valuation
EV/EBITDA34.8834.88—60.4840.21
P/B——51.765.576.27
Growth & Yield
Revenue Growth-58.6%-58.6%-29.6%2.1%—
EPS Growth40.8%40.8%-189.5%53.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +23.1%

Total return

+23.1%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.02 → -0.01

Residual

+23.1%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+23.1%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.